Health: children's drugs need to be "visible hand"

Wu Rui thrush (civil servants)

Release date: 2013-07-17

Source: health

        Accounted for 20% of the total number of patients in our country children patients, drug varieties available but accounts for less than 2% of the total number of drugs. On June 1, the personage inside course of study in child safety use media symposium pointed out that basic on bye medicine for children in our country, the existing safety problems, and cause huge waste. "Beijing daily" (June 2)

        Recently, children's drugs scarce problem, once again become a public issue. At present, the main drug of children less variety, less specification, less dosage forms, mark less and so on several big problems. Medicine for children in most adult medicines to replace, basic on break, this undoubtedly take medicine bring great security hidden danger for the children.

        As for the children's medicine scarce factors, mainly is the children's medicine into high and low profit, clinical trials, and in research and development, transfer, production, use, sell, and many other link lack of policy support. As a result, few companies are willing to research and development of specialized children's medicine. Data shows, in our country, more than 6000 companies, only more than 10 companies specializing in the production of children's drugs, there are children's drugs production enterprise but also more than 30.

        But if only the board to drug firms, is obviously unfair. Because, the pursuit of profit maximization is enterprise's nature, and their rights. In medicine for children under the background of low profit or even lose money, hope enterprise ACTS as to heal the wounded and rescue the dying live thunder feng, not reality.

        Market economy itself also has a lot of blindness and limitations, and sometimes need the "visible hand" of government.

        In fact, the use "visible hand" boost children's drugs, has become the international practice. For example, in the United States, issued many laws and regulations to promote enterprise in research and development of children's medicine, such as 6 months to pediatric drug market protection, involving drug treatment for a rare disease in children, to give 50% tax incentives, to speed up the approval, seven years of market protection policy. European Union, Japan, Korea and so on are also from the establishment of laws and regulations, promote and promote children's drugs research and development production.

        So, want to change children's drugs market, might as well draw lessons from foreign successful experience, at the national level the production, research and development of children's drugs, taxation, market protection, the package tilt of preferential policies. Such as children's medicine production enterprises, making great tax breaks; Architecture children's drug examination and approval of the green channel, so as to arouse the enthusiasm of the Chinese medicine enterprise production research and development of children's medicines, make "basic depend to break off the" children's drugs at an early date come to an end.

The original links: http://www.jkb.com.cn/htmlpage/37/375848.htm?docid=375848&cat=0K&sKeyWord=null